Somewhat Positive News Coverage Somewhat Unlikely to Affect Transgenomic (PRPO) Stock Price
Media headlines about Transgenomic (NASDAQ:PRPO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Transgenomic earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.1688876812289 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, ValuEngine lowered Transgenomic from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st.
Transgenomic (PRPO) traded up 2.7073% on Thursday, reaching $2.1055. The company’s stock had a trading volume of 19,513 shares. Transgenomic has a 12 month low of $1.51 and a 12 month high of $47.70. The company’s market cap is $17.10 million. The company has a 50-day moving average price of $2.01 and a 200 day moving average price of $4.73.
Transgenomic Company Profile
Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.
Receive News & Stock Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related stocks with our FREE daily email newsletter.